Alfuzosin-induced acute hepatitis in a patient with chronic liver disease

Annals of Pharmacotherapy

Volumn 38, Issue 9, 2004, Pages 1443-1445

  Yolcu, Ömer Faruk ^a,c   Köklü, Seyfettin ^a   Köksal, Aydin Ş ^a   Yüksel, Osman ^a   Beyazit, Yavuz ^b   Başar, Ömer ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Alfuzosin; Chronic liver disease; Hepatotoxicity

Indexed keywords

ALFUZOSIN; LIVER ENZYME;

ACUTE HEPATITIS; AGED; ARTICLE; CASE REPORT; CHRONIC LIVER DISEASE; HEPATITIS B VIRUS; HUMAN; HYPERSENSITIVITY; JAUNDICE; LIVER TOXICITY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; SIDE EFFECT;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; HEPATITIS B, CHRONIC; HEPATITIS, TOXIC; LIVER; LIVER FUNCTION TESTS; QUINAZOLINES;

EID: 4143127611     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D633     Document Type: Article

References (10)

1. McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002;62:633-53.
2. Chess-Williams R. The use of alpha-adrenoceptor antagonists in lower urinary tract disease. Expert Opin Pharmacother 2002;3:167-72.
3. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol 1994;74:579-84.
4. Zabala S, Thomson C, Valdearcos S, Gascon A, Piña MA. Alfuzosin-induced hepatotoxicity. J Clin Pharm Ther 2000;25:73-4.
5. 1-blocker. World J Urol 2002;19:405-12.
6. Lukacs B, Blondin P, MacCarthy C, Du BB, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996;29:29-35.
7. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410-29.
8. Jardin A. [Alfuzosin in the treatment of benign prostatic hypertrophy] French. J Urol (Paris) 1993;99:308-10.
9. Martelli A, Pacifico P, Casadei G. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group. Eur Urol 1993;24(suppl 1):28-33.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.